Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy

Blood. 2019 May 23;133(21):2348-2351. doi: 10.1182/blood-2019-01-897637. Epub 2019 Feb 22.

Abstract

There is a Blood Commentary on this article in this issue.

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Female
  • Hematologic Neoplasms* / drug therapy
  • Hematologic Neoplasms* / genetics
  • Hematologic Neoplasms* / pathology
  • Humans
  • Janus Kinase Inhibitors / therapeutic use*
  • Lymphoma* / drug therapy
  • Lymphoma* / genetics
  • Lymphoma* / pathology
  • Male
  • Myeloproliferative Disorders* / drug therapy
  • Myeloproliferative Disorders* / genetics
  • Myeloproliferative Disorders* / pathology
  • Neoplasms, Second Primary* / drug therapy
  • Neoplasms, Second Primary* / genetics
  • Neoplasms, Second Primary* / pathology

Substances

  • Janus Kinase Inhibitors